All Eyes on BioNTech's COVID-19 Vaccine
But the entire pipeline merits attention.
BioNTech (BNTX), founded in Germany in 2008, has become a key player in the development of personalized mRNA cancer treatments. We think the market has assigned a premium to the shares because of the potential upside of the company’s COVID-19 vaccine program, so the valuation does not look compelling at this point. However, this is a company worth watching, with a promising pipeline built on exciting technology.
The emerging biotechnology company does not have any commercialized medicines yet, but its early-stage pipeline and mRNA technology platforms have caught the eye of several large pharmaceutical companies, resulting in collaborations and partnerships. Additionally, the company’s expertise with mRNA has readily lent itself to the development of vaccine candidates for COVID-19, garnering investor enthusiasm as the world awaits a viable vaccine.
Anna Baran does not own shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.